Have a feature idea you'd love to see implemented?
Let us know!
FATE Fate Therapeutics Inc
Price (delayed)
$1.68
Market cap
$191.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$242.18M
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture
Highlights
FATE's EPS is up by 7% year-on-year and by 3.5% since the previous quarter
The debt has declined by 6% year-on-year
The gross profit has dropped by 87% year-on-year but it has increased by 9% since the previous quarter
FATE's revenue has dropped by 87% year-on-year but it is up by 9% since the previous quarter
The company's equity fell by 10% YoY and by 9% QoQ
The company's quick ratio fell by 10% QoQ and by 6% YoY
Key stats
What are the main financial stats of FATE
Market
Valuations
Earnings
Shares outstanding
113.89M
Market cap
$191.34M
Enterprise value
$242.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
14.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.01
Revenue
$13.45M
Gross profit
$13.45M
Net income
-$178.23M
EBIT
-$178.23M
EBITDA
-$159.2M
Free cash flow
-$132.53M
Per share
Balance sheet
Liquidity
EPS
-$1.65
EPS diluted
-$1.65
Free cash flow per share
-$1.13
Book value per share
$3.18
Revenue per share
$0.11
TBVPS
$4.2
Total assets
$494.97M
Total liabilities
$132.64M
Debt
$98.98M
Equity
$362.33M
Working capital
$272.87M
Debt to equity
0.27
Current ratio
8.29
Quick ratio
8.32
Net debt/EBITDA
-0.32
Margins
Efficiency
Dividend
EBITDA margin
-1,183.9%
Gross margin
100%
Net margin
-1,325.4%
Operating margin
-1,462.1%
Return on assets
-34%
Return on equity
-45.9%
Return on invested capital
-34.7%
Return on capital employed
-39%
Return on sales
-1,325.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FATE stock price
How has the Fate Therapeutics stock price performed over time
Intraday
1.2%
1 week
-8.2%
1 month
-24.32%
1 year
-45.1%
YTD
-55.08%
QTD
-52%
Financial performance
How have Fate Therapeutics's revenue and profit performed over time
Revenue
$13.45M
Gross profit
$13.45M
Operating income
-$196.6M
Net income
-$178.23M
Gross margin
100%
Net margin
-1,325.4%
The gross profit has dropped by 87% year-on-year but it has increased by 9% since the previous quarter
FATE's revenue has dropped by 87% year-on-year but it is up by 9% since the previous quarter
The operating margin has grown by 8% from the previous quarter
The net margin rose by 7% since the previous quarter
Growth
What is Fate Therapeutics's growth rate over time
Valuation
What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
0.53
P/S
14.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.01
FATE's EPS is up by 7% year-on-year and by 3.5% since the previous quarter
FATE's price to book (P/B) is 90% lower than its 5-year quarterly average of 5.4 and 56% lower than its last 4 quarters average of 1.2
The company's equity fell by 10% YoY and by 9% QoQ
FATE's revenue has dropped by 87% year-on-year but it is up by 9% since the previous quarter
The stock's price to sales (P/S) is 84% less than its 5-year quarterly average of 90.6 and 68% less than its last 4 quarters average of 45.6
Efficiency
How efficient is Fate Therapeutics business performance
Fate Therapeutics's return on assets has decreased by 21% YoY and by 4% QoQ
The ROE has contracted by 20% YoY and by 4.1% from the previous quarter
The ROIC has contracted by 20% YoY and by 3.9% from the previous quarter
FATE's return on sales is up by 7% since the previous quarter
Dividends
What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FATE.
Financial health
How did Fate Therapeutics financials performed over time
FATE's current ratio is down by 10% from the previous quarter and by 6% YoY
The company's quick ratio fell by 10% QoQ and by 6% YoY
The debt is 73% smaller than the equity
The company's equity fell by 10% YoY and by 9% QoQ
The company's debt to equity rose by 8% QoQ and by 3.8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.